Exclusive-US FDA Finds Widely Used Asthma Drug Impacts the Brain
6 天之前 · The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone, according to FDA slides …
Exclusive: US FDA finds widely used asthma drug impacts the brain
5 天之前 · Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler. ... Reuters, the news and media division of Thomson …
Study shows Singulair linked to serious mental health issues
5 天之前 · By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved …
U.S. FDA reportedly finds widely used asthma drug impacts the brain
5 天之前 · The researchers found that the drug, sold under the brand name Singulair, attaches to multiple brain receptors critical to psychiatric functioning.
Merck’s Former Asthma Blockbuster Singulair Could Be
6 天之前 · FDA researchers have found new evidence of a molecular link between Merck ’s former blockbuster asthma drug montelukast—which is now marketed by spinoff Organon …
U.S. FDA finds widely used asthma drug impacts the brain - CTV News
5 天之前 · By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved …
US FDA finds widely used asthma drug impacts the brain
5 天之前 · By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved …
F.D.A. Warned of Mental Side Effects from Asthma Drug, Singulair…
2024年1月9日 · The agency’s risk-benefit calculus for montelukast has weighed its psychiatric risks against its wide use in treating many patients for asthma, which can be deadly.
FDA Requires Stronger Warning About Risk of Neuropsychiatric …
The FDA is requiring a boxed warning for montelukast (sold under the brand name Singulair and in generic form) to strengthen an existing warning about the risk of neuropsychiatric events.
Boxed Warning about mental health side effects for Singulair
FDA is requiring a Boxed Warning stating that serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking montelukast (Singulair).